 |
|
Cholesterol Redux
Basil M. Rifkind, MD, FRCP;
Lawrence D. Grouse, MD, PhD
JAMA. 1990;264(23):3060-3061.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
In the 4 years since THE JOURNAL's last issue focusing on cholesterol, evidence of the crucial role of serum cholesterol levels in atherosclerosis has continued to accumulate. At the same time, great progress has been made in clinical and population-based efforts to confront this major health risk. The leadership of government health agencies, medical organizations, and the media in cholesterol education, much of it coordinated through the mechanism of the National Cholesterol Education Program, has brought cholesterol management from an arcane backwater to a matter of public policy.
Impressive scientific documentation naturally accompanies this newfound respectability. Of particular note are the outcomes of six controlled angiographic trials of total cholesterol or low-density lipoprotein cholesterol lowering with or without high-density lipoprotein cholesterol increase1-7; two of these studies are described in this issue. These provide evidence that treatment will alter the natural history of atherosclerotic lesions—progression of lesions can be
. . . [Full Text PDF of this Article]
Author Affiliations
From the Lipid Metabolism—Atherogenesis Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (Dr Rifkind), and Medical Communication Resources, Inc, Santa Monica, Calif (Dr Grouse),
Footnotes
Reprint requests to Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Federal Bldg, Room 401, Bethesda, MD 20892 (Dr Rifkind).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
